Safety and immunologic response of a viral vaccine to prostate- specific antigen in combination with radiation therapy when metronomic-dose interleukin 2 is used as an adjuvant

Clinical Cancer Research

Volumn 14, Issue 16, 2008, Pages 5284-5291

  Lechleider, Robert J ^a,d   Arlen, Philip M ^a   Tsang, Kwong Yok ^a   Steinberg, Seth M ^b   Yokokawa, Junko ^a   Cereda, Vittore ^a   Camphausen, Kevin ^a   Schlom, Jeffrey ^a,c   Dahut, William L ^c   Gulley, James L ^a  

^a Lab of Tumor Immunology and Biology   (United States)

^b Office of the Director   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HLA A2 ANTIGEN; INTERLEUKIN 2; PROSTATE SPECIFIC ANTIGEN; VACCINIA VACCINE; CANCER VACCINE; IMMUNOLOGICAL ADJUVANT;

ADJUVANT THERAPY; ADULT; AGED; ANOREXIA; ARTHRALGIA; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED STUDY; DEHYDRATION; DIARRHEA; DRUG DOSE REDUCTION; DRUG MEGADOSE; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; EXTERNAL BEAM RADIOTHERAPY; FATIGUE; FEVER; FOWLPOX VIRUS; HUMAN; HYPERGLYCEMIA; IMMUNE RESPONSE; INJECTION SITE REACTION; LYMPHOCYTOPENIA; MALE; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; NATURAL KILLER CELL; POXVIRUS; PRIORITY JOURNAL; PROSTATE CANCER; REGULATORY T LYMPHOCYTE; DRUG EFFECT; FLOW CYTOMETRY; GENE VECTOR; GENETICS; IMMUNOLOGY; MIDDLE AGED; PROSTATE TUMOR; RADIOTHERAPY; VACCINIA VIRUS;

ADJUVANTS, IMMUNOLOGIC; AGED; CANCER VACCINES; COMBINED MODALITY THERAPY; FLOW CYTOMETRY; FOWLPOX VIRUS; GENETIC VECTORS; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; INTERLEUKIN-2; KILLER CELLS, NATURAL; MALE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIOTHERAPY; T-LYMPHOCYTES, REGULATORY; VACCINIA VIRUS;

EID: 52649182085     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-5162     Document Type: Article

References (36)

1. Dillioglugil O, Leibman BD, Kattan MW, Seale- Hawkins C, Wheeler TM, Scardino PT. Hazard rates for progression after radical prostatectomy for clinically localized prostate cancer. Urology1997;50:93-9.
2. StameyTA.Yemoto CM, McNealJE, Sigal BM, John stone IM. Prostate cancer is highly predictable: a prognostic equation based on all morphological variables in radical prostatectomy specimens. J Urol 2000; 163:1155-60.
3. Paulson DF, Moul JW.Walther PJ. Radical prostatec to my for clinical stage T1 -2N0M0 prostatic adenocarcinoma: long-term results. J Urol 1990,144:1180-4.
4. Bolla M, Collette L, Blank L, et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet 2002:360:103-6.
5. Bolla M, Gonzalez D, Warde P, et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med 1997;337:295-300.
6. GranforsT, Modig H, Damber JE.Tomic R. Combined orchiectomy and external radiotherapy versus radiotherapy alone for nonmetastatic prostate cancer with or without pelvic lymph node involvement: a prospective randomized study. J Urol 1998;159:2030-4.
7. GranforsT, Modig H, Damber JE.Tomic R. Long-term follow up of a randomized study of locally advanced prostate cancer treated with combined orchiectomy and external radiotherapy versus radiotherapy alone. J Urol 2006;176:544-7.
8. Pilepich MV,Winter K, Lawton CA, etal. Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma-long-term results of phase III RTOG 85-31. Int J Radiat Oncol Biol Phys2005;61:1285-90.
9. Messing EM, Manola J, Sarosdy M, Wilding G, Crawford ED, Trump D. Immediate hormonal therapy compared with observation after radical prostatec to my and pelvic lymphadenectomy in men with node- positive prostate cancer. N Engl J Med 1999:341: 1781-8.
10. Chakraborty M, Abrams SI, Coleman CN, Camphausen K, Schlom J, Hodge JW. External beam radiation of tumors alters phenotype of tumor cells to render them susceptible to vaccine-mediated T-cell killing. Cancer Res 2004;64:4328-37.
11. Kudo-Saito C, Schlom J, Camphausen K, Coleman CN, Hodge JW. The requirement of multimodal therapy (vaccine, local tumor radiation, and reduction of suppressor cells) to eliminate established tumors. Clin Cancer Res 2005;11:4533-44.
12. Hodge JW, Schlom J, Donohue SJ, et al. A recombinant vaccinia virus expressing human prostate specific antigen (PSA): safety and immunogenicity in a non-human primate. Int J Cancer 1995:63:231 -7.
13. Gulley JL, Arlen PM, Bastian A, et al. Combining a recombinant cancer vaccine with standard definitive radiotherapy in patients with localized prostate cancer. Clin Cancer Res 2005;11:3353-62.
14. WaldmannTA. The biology of interleukin-2 and inter- leukin-15: implications for cancer therapy and vaccine design. Nat Rev Immunol 2006;6:595-601.
15. Chang AE, Rosenberg SA. Overview of interleukin- 2 as an immunotherapeutic agent. Semin Surg Oncol 1989;5:385-90.
16. van der Vliet HJ, Koon HB.Yue SC, et al. Effects of the administration of high-dose interleukin-2 on immunoregulatory cell subsets in patients with advanced melanoma and renal cell cancer. Clin Cancer Res 2007;13:2100-8.
17. Pandolfi F, Pierdominici M, Marziali M, et al. Low-dose IL-2 reduces lymphocyte apoptosis and increases naive CD4 cells in HIV-1 patients treated with HAART. Clin Immunol 2000;94:153-9.
18. Shah MH, Freud AG, Benson DM, Jr., et al. A phase I study of ultra low dose interleukin-2 and stem cell factor in patients with HIV infection or HIV and cancer. Clin Cancer Res 2006;12:3993-6.
19. Lalezari JP, Beal JA, Ruane PJ, et al. Low-dose daily subcutaneous interleukin-2 in combination with highly active antiretroviral therapy in HIV+ patients: a randomized controlled trial. HIV Clin Trials 2000;1: 1 -15.
20. Caligiuri MA, Murray C, Soiffer RJ, et al. Extended continuous infusion low-dose recombinant interleukin-2 in advanced cancer: prolonged immunomodulation without significant toxicity. J Clin Oncol 1991;9: 2110-9.
21. Caligiuri MA, Murray C, Robertson MJ, et al. Selective modulation of human natural killer cells in vivo after prolonged infusion of low dose recombinant interleukin 2. J Clin lnvest1993;91:123-32.
22. Cesana GC, DeRaffele G, Cohen S, et al. Characterization of CD4+CD25+ regulatory Tcells in patients treated with high-dose interleukin-2 for metastatic melanoma or renal cell carcinoma. J Clin Oncol 2006; 24:1169-77.
23. Hoffmann P, Eder R, Kunz-Schughart LA, Andreesen R, Edinger M. Large-scale in vitro expansion of polyclonal human CD4(+)CD25high regulatoryTcells. Blood 2004;104:895-903.
24. A'Hern RP. Sample size tables for exact single-stage phase II designs. Stat Med 2001;20:859-66.
25. Brinkmann U,Vasmatzis G, Lee B, Pastan I. Novel genes in the PAGE and GAGE family of tumor antigens found by homology walking in the dbEST database. Cancer Res 1999;59:1445-8.
26. Gasparini G. Metronomic scheduling: the future of chemotherapy? Lancet Oncol 2001;2:733-40.
27. Kerbel RS, Kamen BA. The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer 2004;4: 423-36.
28. Lenardo MJ. Fas and the art of lymphocyte maintenance. J Exp Med 1996;183:721 -4.
29. Khatri VP, FehnigerTA, Baiocchi RA, etal. Ultra low dose interleukin-2 therapy promotes a type 1 cytokine profile in vivo in patients with AIDS and AIDS-associated malignancies. J Clin lnvest1998;101:1373-8.
30. Sereti I, Herpin B, Metcalf JA, et al. CD4 Tcell expansions are associated with increased apoptosis rates of T lymphocytes during IL-2 cycles in HIV infected patients. AIDS 2001;15:1765-75.
31. Aragon-ChingJB, Williams KM, GulleyJL. Impact of androgen-deprivation therapy on the immune system: implications for combination therapy of prostate cancer. Front Biosci 2007;12:4957 -71.
32. Zhang H, Chua KS, Guimond M, et al. Lymphopenia and interleukin-2 therapy alter homeostasis of CD4+CD25+ regulatoryTcells. Nat Med 2005;11: 1238-43.
33. + regulatory Tcells in the peripheral blood of patients with prostate cancer. Clin Cancer Res 2008;14:1032-40.
34. Meropol NJ, Barresi GM, Fehniger TA, Hitt J, Franklin M, Caligiuri MA. Evaluation of natural killer cell expansion and activation in vivo with daily subcutaneous low-dose interleukin-2 plus periodic intermediate-dose pulsing. Cancer Immunol Immunother 1998;46:318-26.
35. FehnigerTA, Bluman EM, Porter MM, et al. Potential mechanisms of human natural killer cell expansion in vivo during low-dose IL-2 therapy. J Clin Invest 2000;106:117-24.
36. Kerst JM, Bex A, Mallo H, et al. Prolonged low dose IL-2 and thalidomide in progressive metastatic renal cell carcinoma with concurrent radiotherapy to bone and/or soft tissue metastasis: a phase II study. Cancer Immunol Immunother 2005;54:926-31.